These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457 [TBL] [Abstract][Full Text] [Related]
3. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. Tilden AB; Itoh K; Balch CM J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
5. Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells. Bensussan A; Lagabrielle JF; Castaigne S; Boisson N; Miclea JM; Benbunan M; Degos L Nouv Rev Fr Hematol (1978); 1989; 31(2):129-32. PubMed ID: 2528119 [TBL] [Abstract][Full Text] [Related]
6. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody. Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231 [TBL] [Abstract][Full Text] [Related]
7. CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. De Maria A; Malnati M; Moretta A; Pende D; Bottino C; Casorati G; Cottafava F; Melioli G; Mingari MC; Migone N Eur J Immunol; 1987 Dec; 17(12):1815-9. PubMed ID: 2961576 [TBL] [Abstract][Full Text] [Related]
8. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. Damle NK; Doyle LV; Bradley EC J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965 [TBL] [Abstract][Full Text] [Related]
9. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors. Whiteside TL; Wang YL; Selker RG; Herberman RB Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433 [TBL] [Abstract][Full Text] [Related]
10. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1. van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018 [TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype. Patel SS; Thiele DL; Lipsky PE J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232 [TBL] [Abstract][Full Text] [Related]
12. Morphologic and functional characterization of human peripheral blood T cells expressing the T cell receptor gamma/delta. Ferrini S; Zarcone D; Viale M; Cerruti G; Millo R; Moretta A; Grossi CE Eur J Immunol; 1989 Jul; 19(7):1183-8. PubMed ID: 2527156 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. Patel SS; Wacholtz MC; Duby AD; Thiele DL; Lipsky PE J Immunol; 1989 Aug; 143(4):1108-17. PubMed ID: 2526180 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures. Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621 [TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of anti-CD3-induced activated killer cells. Yun YS; Hargrove ME; Ting CC Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087 [TBL] [Abstract][Full Text] [Related]
17. Two-color flow cytometry and functional analysis of lymphocytes cultured from human renal allografts: identification of a Leu-2+3+ subpopulation. Preffer FI; Colvin RB; Leary CP; Boyle LA; Tuazon TV; Lazarovits AI; Cosimi AB; Kurnick JT J Immunol; 1986 Nov; 137(9):2823-30. PubMed ID: 3093583 [TBL] [Abstract][Full Text] [Related]
18. Clonal analysis of CD4-CD8- human thymocytes expressing a T cell receptor gamma/delta chain. Direct evidence for the de novo expression of CD8 surface antigen and of cytolytic activity against tumor targets. Mingari MC; Varese P; Bottino C; Melioli G; Moretta A; Moretta L Eur J Immunol; 1988 Nov; 18(11):1831-4. PubMed ID: 2974427 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959 [TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells. Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]